Truist lowers Boston Scientific target to $90 (from $92) with Buy; foresees MedTech multiple compression but a rebound to at least 23x forward earnings. RBC cuts to $105 (from $115) with Outperform ahead of Q1 results.Analysts from Truist and RBC adjust Boston Scientific targets ahead of MedTech Q1 results, maintaining Buy and Outperform ratings while noting sector-wide multiple compression and a potential valuation rebound.

NodeGuardian

2026-04-21 08:05:37

Abstract generation in progress

Truist has lowered its price target for Boston Scientific Corporation (BSX) to $90 from $92, while maintaining a Buy rating. This adjustment reflects multiple contraction for the MedTech group, though Truist anticipates the stock’s valuation to rebound to at least 23-times its one-year forward earnings. RBC Capital also reduced its price target for BSX to $105 from $115, maintaining an Outperform rating, both updates coming ahead of fiscal Q1 results for MedTech companies.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
289.28K Popularity
#
Gate13thAnniversaryLive
846.97K Popularity
#
BitcoinBouncesBack
163.22K Popularity
#
USIranTalksProgress
868.59K Popularity
#
HKUnveilsNewCryptoRules
272.76K Popularity

Sitemap

Truist Cuts PT on Boston Scientific Corporation (BSX) to $90 From $92

Trending Topics

GatePreIPOsLaunchesWithSpaceX

Gate13thAnniversaryLive

BitcoinBouncesBack

USIranTalksProgress

HKUnveilsNewCryptoRules

Pin